250 related articles for article (PubMed ID: 34696440)
21. Mutational Hotspot in the SARS-CoV-2 Spike Protein N-Terminal Domain Conferring Immune Escape Potential.
Kubik S; Arrigo N; Bonet J; Xu Z
Viruses; 2021 Oct; 13(11):. PubMed ID: 34834921
[TBL] [Abstract][Full Text] [Related]
22. Low-dose in vivo protection and neutralization across SARS-CoV-2 variants by monoclonal antibody combinations.
Dussupt V; Sankhala RS; Mendez-Rivera L; Townsley SM; Schmidt F; Wieczorek L; Lal KG; Donofrio GC; Tran U; Jackson ND; Zaky WI; Zemil M; Tritsch SR; Chen WH; Martinez EJ; Ahmed A; Choe M; Chang WC; Hajduczki A; Jian N; Peterson CE; Rees PA; Rutkowska M; Slike BM; Selverian CN; Swafford I; Teng IT; Thomas PV; Zhou T; Smith CJ; Currier JR; Kwong PD; Rolland M; Davidson E; Doranz BJ; Mores CN; Hatziioannou T; Reiley WW; Bieniasz PD; Paquin-Proulx D; Gromowski GD; Polonis VR; Michael NL; Modjarrad K; Joyce MG; Krebs SJ
Nat Immunol; 2021 Dec; 22(12):1503-1514. PubMed ID: 34716452
[TBL] [Abstract][Full Text] [Related]
23. Structural and functional ramifications of antigenic drift in recent SARS-CoV-2 variants.
Yuan M; Huang D; Lee CD; Wu NC; Jackson AM; Zhu X; Liu H; Peng L; van Gils MJ; Sanders RW; Burton DR; Reincke SM; Prüss H; Kreye J; Nemazee D; Ward AB; Wilson IA
Science; 2021 Aug; 373(6556):818-823. PubMed ID: 34016740
[TBL] [Abstract][Full Text] [Related]
24. Structural basis for continued antibody evasion by the SARS-CoV-2 receptor binding domain.
Nabel KG; Clark SA; Shankar S; Pan J; Clark LE; Yang P; Coscia A; McKay LGA; Varnum HH; Brusic V; Tolan NV; Zhou G; Desjardins M; Turbett SE; Kanjilal S; Sherman AC; Dighe A; LaRocque RC; Ryan ET; Tylek C; Cohen-Solal JF; Darcy AT; Tavella D; Clabbers A; Fan Y; Griffiths A; Correia IR; Seagal J; Baden LR; Charles RC; Abraham J
Science; 2022 Jan; 375(6578):eabl6251. PubMed ID: 34855508
[TBL] [Abstract][Full Text] [Related]
25. Sensitivity of SARS-CoV-2 B.1.1.7 to mRNA vaccine-elicited antibodies.
Collier DA; De Marco A; Ferreira IATM; Meng B; Datir RP; Walls AC; Kemp SA; Bassi J; Pinto D; Silacci-Fregni C; Bianchi S; Tortorici MA; Bowen J; Culap K; Jaconi S; Cameroni E; Snell G; Pizzuto MS; Pellanda AF; Garzoni C; Riva A; ; Elmer A; Kingston N; Graves B; McCoy LE; Smith KGC; Bradley JR; Temperton N; Ceron-Gutierrez L; Barcenas-Morales G; ; Harvey W; Virgin HW; Lanzavecchia A; Piccoli L; Doffinger R; Wills M; Veesler D; Corti D; Gupta RK
Nature; 2021 May; 593(7857):136-141. PubMed ID: 33706364
[TBL] [Abstract][Full Text] [Related]
26. Emergence of Multiple SARS-CoV-2 Antibody Escape Variants in an Immunocompromised Host Undergoing Convalescent Plasma Treatment.
Chen L; Zody MC; Di Germanio C; Martinelli R; Mediavilla JR; Cunningham MH; Composto K; Chow KF; Kordalewska M; Corvelo A; Oschwald DM; Fennessey S; Zetkulic M; Dar S; Kramer Y; Mathema B; Germer S; Stone M; Simmons G; Busch MP; Maniatis T; Perlin DS; Kreiswirth BN
mSphere; 2021 Aug; 6(4):e0048021. PubMed ID: 34431691
[TBL] [Abstract][Full Text] [Related]
27. Glycan Masking of Epitopes in the NTD and RBD of the Spike Protein Elicits Broadly Neutralizing Antibodies Against SARS-CoV-2 Variants.
Lin WS; Chen IC; Chen HC; Lee YC; Wu SC
Front Immunol; 2021; 12():795741. PubMed ID: 34925381
[TBL] [Abstract][Full Text] [Related]
28. Epitopes of an antibody that neutralizes a wide range of SARS-CoV-2 variants in a conserved subdomain 1 of the spike protein.
Ishimaru H; Nishimura M; Shigematsu H; Marini MI; Hasegawa N; Takamiya R; Iwata S; Mori Y
J Virol; 2024 May; 98(5):e0041624. PubMed ID: 38624232
[TBL] [Abstract][Full Text] [Related]
29. Mapping mutations to the SARS-CoV-2 RBD that escape binding by different classes of antibodies.
Greaney AJ; Starr TN; Barnes CO; Weisblum Y; Schmidt F; Caskey M; Gaebler C; Cho A; Agudelo M; Finkin S; Wang Z; Poston D; Muecksch F; Hatziioannou T; Bieniasz PD; Robbiani DF; Nussenzweig MC; Bjorkman PJ; Bloom JD
Nat Commun; 2021 Jul; 12(1):4196. PubMed ID: 34234131
[TBL] [Abstract][Full Text] [Related]
30. SARS-CoV-2 Variants, RBD Mutations, Binding Affinity, and Antibody Escape.
Yang L; Li J; Guo S; Hou C; Liao C; Shi L; Ma X; Jiang S; Zheng B; Fang Y; Ye L; He X
Int J Mol Sci; 2021 Nov; 22(22):. PubMed ID: 34829998
[TBL] [Abstract][Full Text] [Related]
31. Mutation-induced changes in the receptor-binding interface of the SARS-CoV-2 Delta variant B.1.617.2 and implications for immune evasion.
Baral P; Bhattarai N; Hossen ML; Stebliankin V; Gerstman BS; Narasimhan G; Chapagain PP
Biochem Biophys Res Commun; 2021 Oct; 574():14-19. PubMed ID: 34425281
[TBL] [Abstract][Full Text] [Related]
32. High genetic barrier to SARS-CoV-2 polyclonal neutralizing antibody escape.
Schmidt F; Weisblum Y; Rutkowska M; Poston D; DaSilva J; Zhang F; Bednarski E; Cho A; Schaefer-Babajew DJ; Gaebler C; Caskey M; Nussenzweig MC; Hatziioannou T; Bieniasz PD
Nature; 2021 Dec; 600(7889):512-516. PubMed ID: 34544114
[TBL] [Abstract][Full Text] [Related]
33. Characterization of MW06, a human monoclonal antibody with cross-neutralization activity against both SARS-CoV-2 and SARS-CoV.
Jiang W; Wang J; Jiao S; Gu C; Xu W; Chen B; Wang R; Chen H; Xie Y; Wang A; Li G; Zeng D; Zhang J; Zhang M; Wang S; Wang M; Gui X
MAbs; 2021; 13(1):1953683. PubMed ID: 34313527
[TBL] [Abstract][Full Text] [Related]
34. SARS-CoV-2 escape from a highly neutralizing COVID-19 convalescent plasma.
Andreano E; Piccini G; Licastro D; Casalino L; Johnson NV; Paciello I; Dal Monego S; Pantano E; Manganaro N; Manenti A; Manna R; Casa E; Hyseni I; Benincasa L; Montomoli E; Amaro RE; McLellan JS; Rappuoli R
Proc Natl Acad Sci U S A; 2021 Sep; 118(36):. PubMed ID: 34417349
[TBL] [Abstract][Full Text] [Related]
35. Landscape of human antibody recognition of the SARS-CoV-2 receptor binding domain.
Wheatley AK; Pymm P; Esterbauer R; Dietrich MH; Lee WS; Drew D; Kelly HG; Chan LJ; Mordant FL; Black KA; Adair A; Tan HX; Juno JA; Wragg KM; Amarasena T; Lopez E; Selva KJ; Haycroft ER; Cooney JP; Venugopal H; Tan LL; O Neill MT; Allison CC; Cromer D; Davenport MP; Bowen RA; Chung AW; Pellegrini M; Liddament MT; Glukhova A; Subbarao K; Kent SJ; Tham WH
Cell Rep; 2021 Oct; 37(2):109822. PubMed ID: 34610292
[TBL] [Abstract][Full Text] [Related]
36. Prevalent, protective, and convergent IgG recognition of SARS-CoV-2 non-RBD spike epitopes.
Voss WN; Hou YJ; Johnson NV; Delidakis G; Kim JE; Javanmardi K; Horton AP; Bartzoka F; Paresi CJ; Tanno Y; Chou CW; Abbasi SA; Pickens W; George K; Boutz DR; Towers DM; McDaniel JR; Billick D; Goike J; Rowe L; Batra D; Pohl J; Lee J; Gangappa S; Sambhara S; Gadush M; Wang N; Person MD; Iverson BL; Gollihar JD; Dye JM; Herbert AS; Finkelstein IJ; Baric RS; McLellan JS; Georgiou G; Lavinder JJ; Ippolito GC
Science; 2021 Jun; 372(6546):1108-1112. PubMed ID: 33947773
[TBL] [Abstract][Full Text] [Related]
37. Neutralizing Monoclonal Anti-SARS-CoV-2 Antibodies Isolated from Immunized Rabbits Define Novel Vulnerable Spike-Protein Epitope.
Makdasi E; Levy Y; Alcalay R; Noy-Porat T; Zahavy E; Mechaly A; Epstein E; Peretz E; Cohen H; Bar-On L; Chitlaru T; Cohen O; Glinert I; Achdout H; Israely T; Rosenfeld R; Mazor O
Viruses; 2021 Mar; 13(4):. PubMed ID: 33810465
[TBL] [Abstract][Full Text] [Related]
38. Characterization of a Broadly Neutralizing Monoclonal Antibody against SARS-CoV-2 Variants.
Zakir TS; Meng T; Carmen LCP; Chu JJH; Lin RTP; Prabakaran M
Viruses; 2022 Jan; 14(2):. PubMed ID: 35215823
[TBL] [Abstract][Full Text] [Related]
39. The great escape? SARS-CoV-2 variants evading neutralizing responses.
Prévost J; Finzi A
Cell Host Microbe; 2021 Mar; 29(3):322-324. PubMed ID: 33705702
[TBL] [Abstract][Full Text] [Related]
40. Risk of rapid evolutionary escape from biomedical interventions targeting SARS-CoV-2 spike protein.
Van Egeren D; Novokhodko A; Stoddard M; Tran U; Zetter B; Rogers M; Pentelute BL; Carlson JM; Hixon M; Joseph-McCarthy D; Chakravarty A
PLoS One; 2021; 16(4):e0250780. PubMed ID: 33909660
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
